LMNA mutations are highly prevalent in patients with cardiac conduction disease (CCD), often associated with eventual dilated cardiomyopathy (DCM; Anselme et al., 2013; Barra et al., 2012; Hermida‐Prieto et al., 2004; Keller et al., 2012; Malek et al., 2011; Mounkes et al., 2005; Olaopa et al., 2018; Saj et al., 2010; Shaw et al., 2002; Zaragoza et al., 2016). The gene discussed is LMNA; the disease is heart conduction disease.